Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.0.1500407
European Journal of Endocrinology, Vol 150, Issue 4, 407-414
Copyright © 2004 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krassas, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krassas, G.

Articles

Treatment of juvenile Graves' disease and its ophthalmic complication: the 'European way'

GE Krassas

Department of Endocrinology, Diabetes and Metabolism, Panagia General Hospital, Thessaloniki, Greece. krassas@the.forthnet.gr

Three treatment modalities are available for Graves' disease: antithyroid drugs, surgery and radioactive iodine (RAI). None has been shown to be ideal or superior to the others. There are wide differences between individual physicians and between the physicians in different countries on the optional treatment for childhood hyperthyroidism. While antithyroid drugs remain the initial treatment of choice in almost all the medical centers in Europe, with surgery being used mainly to deal with antithyroid failures, radioiodine is preferred by only a small percentage of physicians for this group of patients. In the USA, on the contrary, radioiodine treatment of thyrotoxicosis in children has strong advocates, who emphasize the safety, simplicity and economic advantages of iodine-131 ablation, which should be considered more commonly in children. Until now, the available data have shown no significant increase in thyroid neoplasia, gonadal injury or congenital abnormalities in the offspring of older children and adults receiving RAI for thyrotoxicosis. Given the considerable increase in the risk of thyroid cancer in young children exposed to external radiation, it has been hypothesized that there may be a small increase in the risk of thyroid cancer in young children treated with RAI. Until long-term data on safety are available, specifically for young children, differences between the physicians in different countries will remain.


This article has been cited by other articles:


Home page
IOVSHome page
K. K. L. Chong, S. W. Y. Chiang, G. W. K. Wong, P. O. S. Tam, T.-K. Ng, Y.-J. Hu, G. H. F. Yam, D. S. C. Lam, and C.-P. Pang
Association of CTLA-4 and IL-13 Gene Polymorphisms with Graves' Disease and Ophthalmopathy in Chinese Children
Invest. Ophthalmol. Vis. Sci., June 1, 2008; 49(6): 2409 - 2415.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
A. Iagaru and I. R. McDougall
Treatment of Thyrotoxicosis
J. Nucl. Med., March 1, 2007; 48(3): 379 - 389.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
G E Krassas, M Segni, and W M Wiersinga
Childhood Graves' ophthalmopathy: results of a European questionnaire study
Eur. J. Endocrinol., October 1, 2005; 153(4): 515 - 521.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 European Society of Endocrinology.